Tempus AI Stock News

Tempus AI is being monitored by journalists and investors worldwide. We gather the latest Tempus AI news here.

Tempus AI Stock Press Releases

Tempus AI regularly publishes news on the company's website that are relevant for investors.

Tempus AI News 2026

This page contains all current news, analysis and press releases for Tempus AI stock (TEM, ISIN: US88023B1035). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Tempus AI.

Tempus AI Stock

Tempus AI Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes.